Gastric cancer recurrent Diagnostics

Physical Examination and Medical History

Every follow-up visit begins with a thorough physical examination and review of your medical history. Your doctor will ask about any new symptoms you've experienced, changes in your eating habits, unexplained weight changes, or any discomfort. During the physical exam, they will feel your abdomen for any masses, check for swelling or fluid accumulation, and assess your overall health status. While physical examination alone cannot definitively diagnose recurrence, it provides valuable clues that guide further testing.2

Blood Tests and Tumor Markers

Blood tests play an important role in monitoring for recurrence, though they cannot diagnose it on their own. Doctors often check for tumor markers, which are substances produced by cancer cells or by the body in response to cancer. Common tumor markers for gastric cancer include CEA (carcinoembryonic antigen) and CA 19-9. Rising levels of these markers over time may suggest cancer recurrence, though they can also be elevated for other reasons. Blood tests also help assess your overall health, checking for anemia, liver function, and kidney function, which can be affected if cancer spreads to these organs.2

Upper Endoscopy

An upper endoscopy, also called esophagogastroduodenoscopy or EGD, is one of the most direct ways to examine the remaining stomach tissue and the connection between the esophagus and what remains of the stomach after surgery. During this procedure, a thin, flexible tube with a camera on the end is passed through your mouth and down into your digestive tract. The doctor can see the lining of these structures in real time and look for suspicious areas. If anything abnormal is found, small tissue samples (biopsies) can be taken during the same procedure for laboratory analysis. Upper endoscopy is particularly useful for detecting locoregional recurrence—cancer that comes back near the surgical site.2

Computed Tomography Scans

CT scans (computed tomography scans) are imaging tests that use X-rays and computer technology to create detailed, cross-sectional pictures of the inside of your body. CT scans of the chest, abdomen, and pelvis are commonly performed to look for signs of recurrent gastric cancer. These scans can reveal tumors in the remaining stomach tissue, nearby lymph nodes, the liver, lungs, and the peritoneum. CT scans are typically done every two to three months during the first few years after surgery, when the risk of recurrence is highest, and then less frequently as time goes on.2

Other Imaging Studies

Depending on your situation, your doctor may recommend additional imaging tests. An abdominal ultrasound can help examine organs like the liver and look for fluid buildup in the abdomen. A PET scan (positron emission tomography scan) may be used to detect areas of active cancer growth throughout the body by showing where cells are using more sugar than normal, which is a characteristic of cancer cells. Chest X-rays can check for cancer spread to the lungs. The choice of imaging depends on what symptoms you have and where recurrence is suspected.2

Biopsy

When imaging or endoscopy reveals a suspicious area, the definitive way to confirm recurrence is through a biopsy—taking a small sample of tissue for examination under a microscope. Biopsies can be obtained during endoscopy, through a needle guided by CT or ultrasound, or during surgery if other methods aren't feasible. Laboratory analysis of the biopsy tells doctors whether cancer cells are present and what type of cancer it is.

Patterns of Recurrence

Understanding where gastric cancer tends to come back helps doctors know which diagnostic tests to emphasize. Research shows that the most common patterns of recurrence are locoregional metastasis (cancer returning near the original site), which accounts for about 43.5% of late recurrences; peritoneal seeding (cancer spreading to the lining of the abdomen), which represents about 34.8%; and hematogenous metastasis (cancer spreading through the bloodstream to distant organs like the liver or lungs), which is less common at about 8.7%. Some patients experience multiple sites of recurrence simultaneously.1

Because locoregional and peritoneal recurrences are more common than distant spread, surveillance strategies often focus on these areas. This is why upper endoscopy and abdominal imaging are central components of follow-up care for gastric cancer survivors.

Standard Enrollment Criteria

Clinical trials for recurrent or advanced gastric cancer typically require confirmation that the cancer has indeed returned. This confirmation comes from a combination of imaging studies and, in most cases, a biopsy showing cancer cells. Trials may have specific requirements about the location of recurrence (local, regional, or distant), the number of previous treatments received, and how well previous treatments worked.3

Molecular and Biomarker Testing

Many modern clinical trials for gastric cancer are designed around specific molecular characteristics of the tumor. This means that in addition to standard diagnostic tests, you may undergo specialized testing to look for particular features of your cancer. One important test checks for HER2 protein levels. HER2-positive gastric cancers, which make too much of this protein, may respond to targeted therapies like trastuzumab. Testing for HER2 status involves examining tumor tissue obtained through biopsy.4

Another critical test looks at microsatellite instability (MSI) or mismatch repair (MMR) status. Tumors that are MSI-high or MMR-deficient have a particular genetic pattern that makes them more likely to respond to immunotherapy drugs. Testing for MSI/MMR status is done on tumor tissue and can determine eligibility for certain immunotherapy clinical trials.5

PD-L1 expression is another biomarker that may be tested. PD-L1 is a protein found on some cancer cells that helps them avoid detection by the immune system. Measuring PD-L1 levels can help predict response to immunotherapy drugs called checkpoint inhibitors. This test also requires tumor tissue analysis.

Performance Status Assessment

Clinical trials also require assessment of your overall health and ability to tolerate treatment. This is measured using standardized scales like the Eastern Cooperative Oncology Group (ECOG) performance status, which rates how well you can carry out daily activities. Your performance status influences which trials you may be eligible for and helps researchers ensure the safety of participants.6

Staging Confirmation

Before enrolling in a clinical trial, comprehensive staging is performed to determine exactly where the cancer has spread. This typically involves CT scans of the chest, abdomen, and pelvis, and possibly additional imaging like PET scans. Some trials are designed specifically for patients with local recurrence, while others focus on distant metastases. Accurate staging ensures you're matched with the most appropriate trial for your situation.3

Routine Laboratory Tests

Clinical trials require baseline laboratory tests to ensure your organs are functioning well enough to handle experimental treatments. These typically include complete blood counts to check your blood cells, comprehensive metabolic panels to assess liver and kidney function, and sometimes additional specialized tests depending on the specific trial. These same tests are repeated periodically during the trial to monitor for side effects.

Prognosis

The outlook for patients with recurrent gastric cancer varies considerably based on several factors. The timing of recurrence plays a significant role in determining prognosis. Early recurrence, which happens within two years after surgery, is generally associated with more aggressive disease. Intermediate recurrence occurs between two and five years after surgery, while late recurrence happens five or more years after treatment. Although late recurrence is uncommon, studies show that younger age and larger tumor size are independent risk factors for cancer returning years after seemingly successful treatment.1

The location and pattern of recurrence also affect prognosis. Locoregional recurrence (cancer returning near the original surgical site) and peritoneal seeding (cancer spreading throughout the abdominal lining) are the most common patterns and tend to be more amenable to treatment than widespread distant metastases. Patients with isolated locoregional recurrence may sometimes be candidates for additional surgery or radiation therapy, potentially offering better outcomes than those with diffuse peritoneal or distant organ spread.1

Individual characteristics matter as well. Factors like overall health status, the ability to tolerate further treatment, nutritional status, and how well previous treatments were tolerated all influence what treatment options are available and how likely they are to help. The specific characteristics of the recurrent tumor—such as whether it's HER2-positive or has high microsatellite instability—can open doors to targeted therapies or immunotherapy, which may improve outcomes compared to traditional chemotherapy alone.5

Survival Rate

Survival statistics for recurrent gastric cancer paint a challenging picture, though outcomes vary widely depending on individual circumstances. Research comparing patients with de novo stage IV gastric cancer (cancer that was already widespread at first diagnosis) to those with recurrent metastatic disease after curative surgery shows some interesting differences. One study found that patients with recurrent metastatic gastric cancer had a median overall survival of 14.4 months, compared to 11.6 months for those with de novo stage IV disease. This difference suggests that patients who develop recurrence after initially successful surgery may have somewhat better outcomes than those whose cancer was advanced from the start.6

However, even with modern treatments, the five-year survival rate for patients with disseminated recurrent gastric cancer remains very low. For patients with localized distal gastric cancer that's confined to resectable regional disease, survival rates can approach 50%, but once cancer has spread beyond regional lymph nodes to distant sites, long-term survival becomes much less likely.3

Among patients who experience recurrence, those with early recurrence (within two years) face the most challenging prognosis. The overall recurrence rate after curative surgery is approximately 20.5%, with the majority of these recurrences happening in the first two years. Late recurrence, though less common at 8.6% of all recurrences, can still occur and requires continued vigilance even years after successful treatment.1

It's important to remember that survival statistics are based on large groups of patients and cannot predict what will happen to any individual person. Advances in treatment, including new targeted therapies and immunotherapy approaches, continue to improve outcomes for some patients with recurrent gastric cancer. Your medical team can provide more personalized information based on your specific situation, the characteristics of your cancer, and the treatment options available to you.